Dr. Raushan Kurmasheva’s laboratory has been awarded a $400K NCI SBIR Phase II grant titled “Enhanced overall survival in high-risk pediatric tumors using a novel oral small molecule.”

January 7, 2026

Federal Awarding Agency: NIH/NCI Project Title: Enhanced overall survival in high-risk pediatric tumors using a novel oral small molecule. Sub PI: Raushan Kurmasheva, PhD Start: 9/15/25 End: 9/14/27 Amount: $401,844 Project Summary: The research in this NCI-SBIR phase 2 contract focuses on developing a therapeutic for rare pediatric cancers. The original phase 1 contract was [...]